Docking of human rhodopsin mutant (Gly90→Asp) with beta-arrestin and cyanidin 3-rutinoside to cure night blindness

• Published in: Bioinformation Vol. 8; no. 3; pp. 128 - 133
• Main Authors: Kanwal, Shagufta, Nishat, Sumaira, Khan, Muhammad Irfan
• Format: Journal Article
• Language: English
• Published: Singapore Biomedical Informatics 01.01.2012
• Subjects: Hypothesis; Agonist; Rhodopsin; Cyanidin; Molecular Docking; Congenital Night Blindness; Arrestin; Rutinoside
• ISSN: 0973-8894; 0973-2063; 0973-2063
• DOI: 10.6026/97320630008128

Rhodopsin is a visual pigment present in rod cells of retina. It belongs to GPCR family and involves photoisomerization of 11-cis-retinal to all-trans-retinal isomers, conformational changes in rhodopsin and signal transduction cascade to generate a nerve impulse. This signaling pathway has been targeted to eliminate the effect of a mutation (Gly90→Asp) responsible for abnormal activation of G-protein without retinal conformations in the absence of light leading to congenital night blindness. A theoretical model of rhodopsin with induced mutation has been deliberated in order to find potential ligands which can offset this mutational effect. The binding interactions between the target mutated rhodopsin model and potential ligands have been predicted with the help of molecular docking. The results indicated strong functional benefits of ligands as an inhibitor and an agonist for mutated rhodopsin model. Therefore, we propose a new visual cascade model which can initiate the normal signaling of rhodopsin mutant with the help of proposed ligands and can provide a hope for vision in future.